{"paper_id":"89767e13-47d7-4524-aa6f-19243568985a","body_text":"Abstract\nAdenomyosis refers to an estrogen-dependent gynecological benign disease in which the endometrial glands and stroma invade the myometrium, resulting in localized or diffuse adenomyosis. It often combines with uterine fibroids, endometrial polyps, endometriosis, etc. The incidence of adenomyosis ranges from 1 to 70% [1] due to the variation of diagnostic criteria. The main clinical manifestations are progressive dysmenorrhea, chronic pelvic pain, menorrhagia, and infertility. With the improvement of magnetic resonance imaging (MRI), transvaginal ultrasound imaging, and other examination techniques, the detection rate of adenomyosis is also increasing [2, 3]. Although it has been nearly 100 years since the name of the disease is mentioned, the true pathogenesis of adenomyosis is still a mystery. This chapter will discuss and focus on the latest knowledge in the pathogenesis of adenomyosis.\nAccess this chapter\nTax calculation will be finalised at checkout\nPurchases are for personal use only\nSimilar content being viewed by others\nReferences\nGraziano A, et al. Diagnostic findings in adenomyosis: a pictorial review on the major concerns. Eur Rev Med Pharmacol Sci. 2015;19(7):1146–54.\nTellum T, et al. Development of a clinical prediction model for diagnosing adenomyosis. Fertil Steril. 2018;110(5):957–964.e3.\nKaramanidis D, et al. OC01: Transvaginal ultrasonography compared with magnetic resonance imaging for the diagnosis of adenomyosis. Ultrasound Obstet Gynecol. 2018;52(4):555.\nScoutt LM, et al. Junctional zone of the uterus: correlation of MR imaging and histologic examination of hysterectomy specimens. Radiology. 1991;179(2):403–7.\nAgostinho L, et al. MRI for adenomyosis: a pictorial review. Insights Imaging. 2017;8(6):549–56.\nRiggs JC, et al. Cesarean section as a risk factor for the development of adenomyosis uteri. J Reprod Med. 2014;59(1–2):20–4.\nLeyendecker G, Wildt L. A new concept of endometriosis and adenomyosis: tissue injury and repair (TIAR). Horm Mol Biol Clin Invest. 2011;5(2):125–42.\nLi T, Li Y-G, Pu D-M. Matrix metalloproteinase-2 and-9 expression correlated with angiogenesis in human adenomyosis. Gynecol Obstet Investig. 2006;62(4):229–35.\nXiao Y, et al. Expression of integrin β3 and osteopontin in the eutopic endometrium of adenomyosis during the implantation window. Eur J Obstet Gynecol Reprod Biol. 2013;170(2):419–22.\nHricak H, et al. Magnetic resonance imaging of the female pelvis: initial experience. Am J Roentgenol. 1983;141(6):1119–28.\nYifu S. There are some questions about uterine adenopathy. China Fam Plan Obstet Gynecol. 2018;10(1):3–6.\nLeyendecker G, et al. Adenomyosis and endometriosis. Re-visiting their association and further insights into the mechanisms of auto-traumatisation. An MRI study. Arch Gynecol Obstet. 2015;291(4):917–32.\nShaked S, et al. Uterine peristalsis-induced stresses within the uterine wall may sprout adenomyosis. Biomech Model Mechanobiol. 2015;14(3):437–44.\nUduwela A, et al. Endometrial-myometrial interface: relationship to adenomyosis and changes in pregnancy. Obstet Gynecol Surv. 2000;55(6):390–400.\nLiu Jingjing DH. Wangsha the expression and significance of nitric oxide in the smooth muscle cells in the endometrial-myoline junction region of uterine adenopathic patients. Chinese J Obstet Gynecol. 2013;48(007):504–7.\nKyo S, et al. Telomerase activity in gynecological tumors. Clin Cancer Res. 1996;2(12):2023–8.\nXue Q, Zhou Y, Liu Y. Expression of ki67 and CA_ (125) in Adenomyosis. J Pract Obstet Gynecol. 2003;5\nDeng Y, Chunlan H, Xiaoling L. Expression of Survivin in Adenomyosis and its relationship with Bcl-2 and Bax protein. J Med Res. 2006;6\nXiao Y, et al. Expression of integrin beta3 and osteopontin in endometrium of patients with adenomyosis. Zhonghua Fu Chan Ke Za Zhi. 2009;44(5):354–8.\nPolyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265–73.\nAcloque H, et al. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest. 2009;119(6):1438–49.\nAn M, et al. Interaction of macrophages and endometrial cells induces epithelial–mesenchymal transition-like processes in adenomyosis. Biol Reprod. 2017;96(1):46–57.\nKhan KN, et al. Involvement of hepatocyte growth factor-induced epithelial-mesenchymal transition in human adenomyosis. Biol Reprod. 2015;92(2):35. 1-11\nOh SJ, et al. β-Catenin activation contributes to the pathogenesis of adenomyosis through epithelial–mesenchymal transition. J Pathol. 2013;231(2):210–22.\nChen YJ, et al. Oestrogen-induced epithelial–mesenchymal transition of endometrial epithelial cells contributes to the development of adenomyosis. J Pathol. 2010;222(3):261–70.\nSobel V, Zhu Y-S, Imperato-McGinley J. Fetal hormones and sexual differentiation. Obstet Gynecol Clin. 2004;31(4):837–56.\nSpencer TE, et al. Comparative developmental biology of the mammalian uterus. Curr Top Dev Biol. 2005;68:85–122.\nDonnez J, et al. Stereometric evaluation of peritoneal endometriosis and endometriotic nodules of the rectovaginal septum. Hum Reprod. 1996;11(1):224–8.\nEnatsu A, et al. Adenomyosis in a patient with the Rokitansky-Kuster-Hauser syndrome. Fertil Steril. 2000;73(4):862–3.\nGargett CE. Uterine stem cells: what is the evidence? Hum Reprod Update. 2007;13(1):87–101.\nChan RW, Schwab KE, Gargett CE. Clonogenicity of human endometrial epithelial and stromal cells. Biol Reprod. 2004;70(6):1738–50.\nKato K. Stem cells in human normal endometrium and endometrial cancer cells: characterization of side population cells. Kaohsiung J Med Sci. 2012;28(2):63–71.\nLong Wenjie GL, Fudi L, Xin S, Hui L. Stem cells and their relationship with adenomyosis*. Prog Mod Biomed. 2017;17(2):393–5.\nTaylor HS. Endometrial cells derived from donor stem cells in bone marrow transplant recipients. JAMA. 2004;292(1):81–5.\nZhang W-B, et al. A study in vitro on differentiation of bone marrow mesenchymal stem cells into endometrial epithelial cells in mice. Eur J Obstet Gynecol Reprod Biol. 2012;160(2):185–90.\nMorelli SS, Rameshwar P, Goldsmith LT. Experimental evidence for bone marrow as a source of nonhematopoietic endometrial stromal and epithelial compartment cells in a murine model. Biol Reprod. 2013;89(1):1–7.\nDu H, Naqvi H, Taylor HS. Ischemia/reperfusion injury promotes and granulocyte-colony stimulating factor inhibits migration of bone marrow-derived stem cells to endometrium. Stem Cells Dev. 2012;21(18):3324–31.\nIbrahim MG, et al. Ultramicro-trauma in the endometrial-myometrial junctional zone and pale cell migration in adenomyosis. Fertil Steril. 2015;104(6):1475–1483.e3.\nZhang Yumin ZS. The study of pale cells and adenomyosis. Chin J Obstet Gynecol. 2018;1:39.\nZhang X, et al. Endometrial nerve fibers in women with endometriosis, adenomyosis, and uterine fibroids. Fertil Steril. 2009;92(5):1799–801.\nChoi YS, et al. Effects of LNG-IUS on nerve growth factor and its receptors expression in patients with adenomyosis. Growth Factors. 2010;28(6):452–60.\nOta H, Tanaka T. Stromal vascularization in the endometrium during adenomyosis. Microsc Res Tech. 2003;60(4):445–9.\nMu Y, et al. Serum levels of vascular endothelial growth factor and cancer antigen 125 are related to the prognosis of adenomyosis patients after interventional therapy. Int J Clin Exp Med. 2015;8(6):9549.\nLiu X, et al. Corroborating evidence for platelet-induced epithelial-mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation in the development of adenomyosis. Hum Reprod. 2016;31(4):734–49.\nGarcia L, Isaacson K. Adenomyosis: review of the literature. J Minim Invasive Gynecol. 2011;18(4):428–37.\nOta H, et al. Is adenomyosis an immune disease? Hum Reprod Update. 1998;4(4):360–7.\nGaravaglia E, et al. Adenomyosis and its impact on women fertility. Iran J Reprod Med. 2015;13(6):327.\nVannuccini S, et al. Pathogenesis of adenomyosis: an update on molecular mechanisms. Reprod Biomed Online. 2017;35(5):592–601.\nLiu Y, et al. Down-regulation of tumor suppressor PDCD4 expression in endometrium of adenomyosis patients. Current Res Transl Med. 2016;64(3):123–8.\nYe F, Zhang J, Qin J-q. Expression and significance of COX-2 and VEGF in adenomyosis. J Harbin Med Univ. 2006;3\nHuang Y, et al. Expression of tyrosine kinase receptor B in eutopic endometrium of women with adenomyosis. Arch Gynecol Obstet. 2011;283(4):775–80.\nCakmak H, et al. Immune-endocrine interactions in endometriosis. Front Biosci (Elite Ed). 2009;1(2):429–43.\nKeenan JA, et al. Interferon-gamma (IFN-γ) and Interleukin-6 (IL-6) in peritoneal fluid and macrophage-conditioned Media of Women with Endometriosis. Am J Reprod Immunol. 1994;32(3):180–3.\nBergqvist A, et al. Interleukin 1β, interleukin-6, and tumor necrosis factor-α in endometriotic tissue and in endometrium. Fertil Steril. 2001;75(3):489–95.\nYang JH, et al. Increased interleukin-6 messenger RNA expression in macrophage-cocultured endometrial stromal cells in adenomyosis. Am J Reprod Immunol. 2006;55(3):181–7.\nChen C, et al. The microbiota continuum along the female reproductive tract and its relation to uterine-related diseases. Nat Commun. 2017;8(1):1–11.\nAuthor information\nAuthors and Affiliations\nEditor information\nEditors and Affiliations\nRights and permissions\nCopyright information\n© 2021 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.\nAbout this chapter\nCite this chapter\nXiao, F. (2021). The Pathogenesis of Adenomyosis. In: Xue, M., Leng, J., Wong, F. (eds) Adenomyosis. Springer, Singapore. https://doi.org/10.1007/978-981-33-4095-4_2\nDownload citation\nDOI: https://doi.org/10.1007/978-981-33-4095-4_2\nPublished:\nPublisher Name: Springer, Singapore\nPrint ISBN: 978-981-33-4094-7\nOnline ISBN: 978-981-33-4095-4\neBook Packages: MedicineMedicine (R0)","source_license":"CC0","license_restricted":false}